Treatment patterns and clinical outcomes of palbociclib-based therapy received in US community oncology practices

Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Eligible patients receiving palbociclib-based therapy per label in...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2021-03, Vol.17 (9), p.1001-1011
Main Authors: Lin, Junji, McRoy, Lynn, Fisher, Maxine D, Hu, Nan, Davis, Cralen, Mitra, Debanjali, Walker, Mark S
Format: Article
Language:English
Subjects:
advanced breast cancer
metastatic breast cancer
palbociclib
real-world data
real-world progression-free rate
real-world progression-free survival
real-world survival rate
real-world tumor response
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Eligible patients receiving palbociclib-based therapy per label indication from 3 February 2015 to 31 December 2017 were included. Descriptive analyses were conducted for patient characteristics, treatment patterns and clinical outcomes. The study included 233 patients who received palbociclib + aromatase inhibitor (P+AI) and 48 who received palbociclib + fulvestrant (P+F). Real-world progression-free rate for P+AI was 69.8% (46.8%) at 12 (24) months (P+F: 43.5% [39.9%]) months. Real-world survival rate was 89.8% (71.4%) at 12 (24) months (P+F: 76.3% [65.0%]). The study findings are consistent with previous studies of palbociclib-based therapy. Palbociclib, a drug that inhibits cancer cell growth, is approved to treat hormone receptor-positive, HER- advanced breast cancer in combination with hormone therapy drugs, such as aromatase inhibitor (P+AI) or fulvestrant (P+F). Clinical trials indicate that palbociclib is effective in patients with HR+/HER- advanced breast cancer; however, evidence from real-life use of these drugs is limited. This study reviewed the medical records of patients who received P+AI or P+F in US community oncology clinics. After 12 months of treatment with P+AI, 90 in 100 women were still alive and 70 in 100 were living without their cancer getting worse; of those patients who received P+F, 76 in 100 were still alive and 44 in 100 were living without their cancer getting worse. The findings from this study are consistent with previous studies of palbociclib.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2020-0744